View Past PerformanceHypha Labs 대차대조표 건전성재무 건전성 기준 점검 0/6Hypha Labs 의 총 주주 지분은 $-2.8M 이고 총 부채는 $1.8M, 이는 부채 대 자기자본 비율을 -64.7% 로 가져옵니다. 총자산과 총부채는 각각 $159.8K 및 $2.9M 입니다.핵심 정보-64.73%부채/자본 비율US$1.80m부채이자보상배율n/a현금US$82.20k자본-US$2.78m총부채US$2.94m총자산US$159.82k최근 재무 건전성 업데이트공시 • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.모든 업데이트 보기Recent updates공시 • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095공시 • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 19Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) PrototypesHypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants.공시 • Jun 25Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium ProductionHypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.공시 • May 23Hypha Labs, Inc. Announces New Patent FilingHypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions.공시 • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 30Hypha Labs, Inc. Appoints Craig Ellins as Chief Science OfficerHypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror.공시 • Aug 17Digipath, Inc. announced delayed 10-Q filingOn 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17Digipath, Inc. announced delayed 10-Q filingOn 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Dec 31Digipath, Inc. announced delayed annual 10-K filingOn 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Jan 01DigiPath, Inc. announced delayed annual 10-K filingOn 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Jul 07DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive OfficerOn July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company.재무 상태 분석단기부채: FUNI 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.장기 부채: FUNI는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.부채/자본 비율 추이 및 분석부채 수준: FUNI 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.부채 감소: FUNI는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: FUNI 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 0.7 %의 역사적 비율로 계속 감소할 경우 FUNI 의 현금 활주로는 1년 미만입니다.건전한 기업 찾아보기7D1Y7D1Y7D1YConsumer-durables 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 20:29종가2026/05/22 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hypha Labs, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095
공시 • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 19Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) PrototypesHypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants.
공시 • Jun 25Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium ProductionHypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.
공시 • May 23Hypha Labs, Inc. Announces New Patent FilingHypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions.
공시 • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 30Hypha Labs, Inc. Appoints Craig Ellins as Chief Science OfficerHypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror.
공시 • Aug 17Digipath, Inc. announced delayed 10-Q filingOn 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17Digipath, Inc. announced delayed 10-Q filingOn 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Dec 31Digipath, Inc. announced delayed annual 10-K filingOn 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Jan 01DigiPath, Inc. announced delayed annual 10-K filingOn 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Jul 07DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive OfficerOn July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company.